Resolution Therapeutics

top of page

Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies

CEO Amir Hefni describes how this autologous product is designed to work, the investments Resolution has made in its manufacturing...

Company News

Oct 8, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page

Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies

Follow BiotechTV

Sponsors

Sponsor Spotlight